35 results about "Suckling Animals" patented technology

Hypertension in mammalian patients, especially elderly human patients, derived from ingestion of NSAIDs or through the normal aging process is treated by administration to the patient of a vitamin B6 (or derivative) supplement. Where the patient requires the continued administration of an NSAID for pharmacological purposes, the NSAID is administered in conjunction with a vitamin B6 supplement. The invention further provides combination pharmaceutical combinations of an NSAID and a vitamin B6 supplement, e.g. orally administrable tablets or capsules, for use in treating such conditions.

A method and pharmaceutical composition for ceasing milk production, for inducing involution, or for treating infection in a mammary gland of a lactating animal is described. The method is effected by direct administration of calcium chelators to the gland, or upon administration of enzymes which cause production of chelators in situ. The invention can be used to change the physiologic state of a single mammary gland of a lactating animal without significantly affecting the physiologic state of other mammary glands of the same animal. Changes resulting from use of the invention may be either transient or long lasting. The invention is expected to have uses in commercial agriculture and human medicine.

Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

The invention identifies a narrow subset of Mycobacterium latency associated antigens and or epitopes that are capable of eliciting an immune response in vivo and in vitro in a mammal. The invention provides methods and compositions for detection and immunization against latent Mycobacterium infections. These compositions comprise those Mycobacterial latency antigens that are actually capable of eliciting an immune response in vivo, in mammals experiencing a latent Mycobacterium infection. More preferably the compositions comprise those antigens that are preferentially recognized by latently infected individuals and which antigens are not, or to a much lesser extent, recognized in individuals having an active Mycobacterium infection or in individuals having Mycobacterium induced symptoms or diseases, such as in patients infected with M. tuberculosis suffering from tuberculosis disease (TB).

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The invention relates to an antrodia camphorate cyclohexanedione compound used for treating autoimmune diseases and a medical composition thereof. The antrodia camphorate cyclohexanedione compound is about 4-hydroxyl-2, 3-dimethoxy-6-methyl-5(3, 7, 11-trimethyl-2, 6, 10-dodecatrien)-2-cyclohexanedione which is separated from antrodia camphorate extract and can relieve systemic erythromelalgia lupus and other symptoms caused by autoimmune diseases. Antrodia camphorate cyclohexanedione in the invention can reduce the content of urine protein of the mammalians with systemic erythromelalgia lupus and the thickness of the antinuclear antibody in blood, relieves kidney inflammation and lesion, lowers the harm of antinuclear antibody on autogenous tissues, and achieves the effect of treating autoimmune diseases such as systemic erythromelalgia lupus, and the like, and the diseases related to kidney by using natural materials without side effects.

The current invention is based upon administration of a probiotic, B. Lactis NCC2818 to healthy young mammals during the critical weaning period (in infants this period is usually from about 3 months to about 12, 18 or 24 months old), so as to accelerate the young mammal's adaptation to new food. The effectiveness of the invention is evidenced herein by morphological and immunological changes observed in a piglet animal model of weaning. Thus, administration of the probiotic according to the invention had a prophylactic effect, preventing the severe discomfort and pathological states associated with the introduction to novel foods during the weaning period.

Specially designed non-mammalian GnRH analogs resistant to degradation by the tumor tissue enzymes, post-proline peptidases as well as endopeptidases, are disclosed. The GnRH analogs are further defined as analogs of chicken II GnRH, salmon GnRH, or herring GnRH, but can include any non-mammalian GnRH analog with similar amino acid structure. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine or D-Trp or other similar amino acids at position 6 and ethylamide or aza-Gly-amide or similar amides at position 10. These analogs demonstrate preferential binding to tumor cell GnRH receptors that is greater relative to the binding of the mammalian analogs to the tumor cell GnRH receptor. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and it specifically in various treatments as an anti-tumor, anti-proliferation, anti-metastatic and / or an apoptotic agent. The non-mammalian GnRH analogs are also provided in pharmaceutical preparations that may be used clinically for tumor regression when used in very low doses and administered in pulsatile fashion.

The present invention relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.

The invention discloses a fish cream fermented soybean pulp and a production method and an application thereof. The method provided by the invention comprises the following steps of (1) preparing soybean pulp, concentrated fish soluble which is subjected to field preservation treatment and contains 50-75wt% of moisture, and pineapple juice which is subjected to field preservation treatment; (2) mixing the raw materials according to the ratio that 200-500kg of concentrated fish cream is used for each ton of soybean pulp, and 100-200kg of pineapple juice is used for each ton of soybean pulp and adding yeast seeds in the mixture; and (3) performing solid fermentation. The product prepared by the method provided by the invention is particularly suitable for the special nutrition demands of young farmed animals, the product is good in palatability, high in digestibility, and the product further has the natural lactation promotion function, thus, the product can improve the milk quality of suckling animals.

The present invention provides a method for preventing or ameliorating neural damage in a mammalian fetus or a newborn infant, which is caused by maternal gestational hypertension (GH). The method includes orally administering germination activated sporoderm-broken Ganoderma lucidum spores (“GLSs”) to a pregnant mammal having GH. The neural damage includes a decrease in hippocampal cell proliferation and neuron number. The present invention further provides a method for preventing or ameliorating the increased expression of hippocampal hypoxia inducible factor (HIF-1a) and vascular endothelial growth factor (VEGF) in a mammalian embryo caused by maternal GH.

The present invention is based on the surprising discovery of autoantibodies to cytokeratin 18 protein in the serum samples of patients with bronchial asthma and chronic rhinitis, especially in nonallergic patients. The present invention includes diagnostic methods and a diagnostic kit to detect patients with bronchial asthma and chronic rhinitis associated with autoantibodies to cytokeratin 18. The invention also includes methods and kits to prescribe or monitor treatment for patients with bronchial asthma and chronic rhinitis by detecting autoantibodies to cytokeratin 18. The present invention also includes a pharmaceutical formulation comprising cytokeratin 18 protein to protect patients with bronchial asthma and chronic rhinitis associated with autoantibodies to cytokeratin 18. The present invention also includes methods to treat patients with bronchial asthma and chronic rhinitis associated with autoantibodies to cytokeratin 18 using compounds that inhibit the interaction between such autoantibodies and cytokeratin 18 protein.

The invention discloses a novel functional biological feed production process. Raw materials of corns, bean meal and the like are partly subjected to enzymolysis, wherein 1 / 3 of proteins are converted into small peptides by enzymolysis, more than one half of starch is decomposed into monosaccharides of fructose, glucose and the like, the small peptides and the monosaccharides can be directly absorbed and utilized by animal bodies. Each of resistance factor urease, pectin, phytic acid and cellulose in a prepared feed is reduced by about 70%; globulins 7S and 11S of soyabean protein sensitization factors are reduced by about 50%, so that the prepared feed is suitable for being used as a feedstuff in the mouth-open period and a creep feed of young animals, an aquaculture bait as well as a nutrient source of animals the in pregnancy and the lactation period. The biological feed provided by the invention has the advantages of being easy to absorb, capable of reducing the animal diarrhea rate and improving the palatability, simple in production process, small in investment, low in cost, and suitable for large-scale production and popularization.

The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.

A coronary restenosis in a mammal can be prevented or treated by administering a pharmaceutical composition comprising an effective amount of catechin thereto.

Methods and compositions are provided for increasing the feed intake of lactating animals. Incorporation of sodium sulfate decahydrate (glauber salts) into animal feed enhances the feed intake of lactating animals. Glauber salts are particularly effective as feed intake enhancers when the lactating animals are under heat stress conditions. Lactating animals provided with a diet supplemented with glauber salts in the farrowing crate until weaning show an increase in the average daily feed intake compared to animals without glauber salts in their diet.

The invention relates to the field of animal models and particularly discloses an establishment method for a model for promoting tongue cancer development and lymphatic metastasis of mammals. According to the establishment method for the model for promoting tongue cancer development and lymphatic metastasis of the mammals, the mammals are fed with a 4-NQO solution and a NaNO2 solution in sequence for a period of time; the mammals are subjected to normal observation every week and killed randomly for HE staining observation and immunohistochemistry CK8 staining observation; when white patches are generated on the tongue faces of the mammals, invasive carcinoma is found through HE staining observation, and lymphatic metastasis is generated through CK8 staining. The establishment method for the animal model for promoting tongue cancer development and lymphatic metastasis with sodium nitrite is established, the progress of the actually-generated tongue cancer is simulated, and a novel and powerful tool is provided for research on the influences of sodium nitrite on the tongue cancer, treatment research on the tongue cancer and the like.

The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and / or neonatal mortality. According to the present invention delays in parturition that result from maternal and / or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psychomotor stimulants to the parturient mammal prior to and / or during parturition. Said psychomotor stimulant is selected from the group comprising xanthines and amphetamines.

The invention provides a nutrient solution for animals. The nutrient solution solves the problem that the lactating capacity of suckling animals cannot be effectively improved in a nutrient solution for the animals in the prior art. The nutrient solution for the animals is used for improving the lactating capacity of the animals. The nutrient solution is prepared from the following raw materials in parts by weight: 10 to 16 parts of a lactagogue traditional Chinese medicine component, 4 to 10 parts of protein, 2 to 4 parts of degreasing fresh milk, 10 to 20 parts of fructo-oligosaccharide, 2 to 6 parts of fatty acid, 1 to 5 parts of dietary fiber, 2 to 3 parts of a mineral component, 1 to 3 parts of a vitamin component, 0.04 to 0.2 part of a lactation promoting agent, 1 to 2 parts of lactobacillus acidophilus, 1 to 3 parts of a phagostimulant and the balance of water. The lactagogue traditional Chinese medicine component is prepared from the following raw materials: 8 to 12 parts of angelica sinensis, 4 to 10 parts of radix angelicae, 9 to 18 parts of radix bupleuri, 12 to 24 parts of prepared rehmannia root, 6 to 8 parts of pulp of dogwood fruit, 5 to 10 parts of hawthorn, 4 to 8 parts of glossy privet fruit, 8 to 16 parts of roasted malt, 6 to 8 parts of liquorice and 2 to 6 parts of tulips. Lipoic acid and the lactagogue traditional Chinese medicine component are added into the nutrient solution for the animals. The available nutritional level of the nutrient solution is improved, the hormone secretion inside animal bodies is adjusted, the lactating capacity of the suckling animals is improved, and the lactating period is prolonged.

The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and / or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and / or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and / or eclampsia.

The present invention provides a method of treating diabetes, including administering to a mammal diagnosed with diabetes a purified recombinant reg I protein.

The invention relates to medicinal use of leonurine, and in particular provides use of leonurine and pharmaceutical salts thereof for improving estradiol (E2) level of human being or mammals or reducing luteinizing hormone (LH) or follicle stimulating hormone (FSH) level of the human being or the mammals. The novel use of the leonurine is beneficial to clinical practice and therapeutic effectiveness of mifepristone and misoprostol on the early pregnancy before artificial abortion, particularly to the treatment of the incomplete womb restoration after parturition or bleeding after medical abortion.

The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and / or neonatal mortality. According to the present invention delays in parturition that result from maternal and / or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psychomotor stimulants to the parturient mammal prior to and / or during parturition. Said psychomotor stimulant is selected from the group comprising xanthines and amphetamines.

A method of feeding a monogastric mammal, the method including feeding the monogastric mammal a milk replacer during a feeding period and feeding the monogastric mammal a psyllium composition during the feeding period.

This invention relates to an agent which may be used to expel parasites from humans, mammals or birds. The agent of the invention may a vegetable product, Ferula Assafoetida, which is very effective in expelling parasites.

A compound premix capable of improving the lactation ability of animals comprises the following components in parts by weight: 5-30 parts of colostrum powder, 5-35 parts of yolk powder, 2-25 parts of lactoferrin, 3-30 parts of glyceryl monobutyrate, 0.5-8 parts of vitamins, 0.1-8 parts of minerals and 10-70 parts of a carrier, glyceryl monobutyrate and colostrum can greatly promote the mammary gland development of the animals in the lactation period, enhance the lactation ability and improve the lactation ability of the animals in the lactation period. The egg yolk powder and the lactoferrin are added in a compound manner, so that the milk quality is improved, the problem of mammary glands caused by the increase of lactation yield is avoided, the animals in the lactation period can secrete enough milk, sufficient nutrition is provided for the cubs, the cubs can obtain enough immune factors, the immunity and the disease resistance are improved, and the death rate of the cubs is reduced; the weaning weight of the cubs is increased; in addition, the premix can also promote intestinal development of the cubs and weaken or eliminate weaning stress generated when the cubs are weaned or about to be weaned.

The invention discloses a mammal seminal fluid inseminating syringe with quantified and heat-preserving functions. The mammal seminal fluid inseminating syringe comprises a seminal fluid storage piston tube and a disinfectant fluid storage piston tube. The seminal fluid storage piston tube is fixedly connected to the top of the disinfectant fluid storage piston tube. A handle is fixedly connected to the right side of the bottom of the disinfectant fluid storage piston tube. The seminal fluid storage piston tube comprises an inner container and an outer shell. The inner container is fixedly installed inside the outer shell. A closed cavity is formed between the outer shell and the inner container. A micro condenser, a micro heater and a temperature sensor are arranged inside the closed cavity and fixedly connected with the outer wall of the inner container separately. According to the mammal seminal fluid inseminating syringe with the quantified and heat-preserving functions, a worker can effectively and conveniently set the seminal fluid conveying amount in advance through cooperative use of a stop nut and dimension scale lines, effective utilization of seminal fluid is ensured, and operation of the worker is easier.